Navigation Links
Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
Date:5/30/2008

NEW HAVEN, Conn., May 30 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that data from two clinical trials of its lead anticancer agent Cloretazine(R) (VNP40101M) in acute myelogenous leukemia (AML) would be presented in posters at the 2008 American Society of Clinical Oncology (ASCO(R)) Annual Meeting in Chicago, Illinois.

The poster (Abstract #7051) entitled "A double blind placebo-controlled randomized phase III study of high-dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients with first relapse of AML" will be presented at McCormick Place, South Hall A1, Board 38E from 8:00 a.m. to 12:00 p.m. on Saturday, May 31, 2008. A copy of the poster will be available on Vion Pharmaceuticals' website, http://www.vionpharm.com, on May 31, 2008 at 7:00 a.m. Eastern Time.

The poster (Abstract #7025) entitled "A phase II study of VNP40101M in elderly patients with de novo poor risk AML" will be presented at McCormick Place, Room E450a, Board 15 from 2:00 p.m. to 6:00 p.m. on Monday June 2, 2008. A poster discussion will take place at 5:30 p.m. in Room E354a. A copy of the poster will be available on Vion Pharmaceuticals' website, http://www.vionpharm.com, on June 2, 2008 at 1:00 p.m. Eastern Time.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a si
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
2. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
3. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
6. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
7. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
(Date:12/22/2014)... TWi Biotechnology, Inc., today announced that ... TWi Biotechnology,s lead drug candidate, from The State ... for patent application numbered 201180018154.8.  This patent ... metabolite for treatment of type II diabetes.  The ... AC-201 for type II diabetes, and provides a ...
(Date:12/19/2014)...  Newport Corporation (NASDAQ: NEWP ) ... the company,s Board of Directors.  Dr. Kadia is ... of Evans Analytical Group, a leading global provider ... to companies in a wide range of industries.   ... Group, Dr. Kadia spent nine years with Life ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... 2010 CareFusion (NYSE: ... today launched the EnVe™ ventilator , a ... 70-80 pounds lighter than other ventilators with similar ... The EnVe ventilator has the capability to ...
... Dec. 20, 2010 Codexis, Inc. (Nasdaq: CDXS ... Jaffray Clean Technology & Renewables Conference, to be held in ... be made by Robert Lawson, Senior Vice President and Chief ... noon Eastern Time.  A webcast and replay will be available ...
Cached Medicine Technology:CareFusion Launches EnVe Ventilator, Weighing 10 Times Less Than Traditional Critical Care Ventilators 2CareFusion Launches EnVe Ventilator, Weighing 10 Times Less Than Traditional Critical Care Ventilators 3
(Date:12/24/2014)... Dr. Ronald Receveur, a New ... dental implants in a day, has written ... overusing teeth-whitening treatments. , In his blog published ... Receveur writes that overusing teeth-whitening treatments can lead to ... enamel. , “Because teeth-whitening treatments are available ...
(Date:12/24/2014)... News) -- Longer and colder body cooling does not reduce ... from a lack of oxygen, a new study finds. ... condition -- called hypoxic ischemic encephalopathy -- can be reduced ... Fahrenheit) for 72 hours, experts say. Research has shown ... so this study examined if the same would be true ...
(Date:12/22/2014)... December 22, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Medical Center in Oceanside, Calif. The top ... E. Smith has recently placed more than 900 healthcare ... a community owned, 397-bed, Gold Seal-approved, full-service acute-care hospital ...
(Date:12/22/2014)... 22, 2014 Sagacious Consultants, the premier ... subscription option to their ad hoc report writing service ... Customers can sign up for an annual subscription and ... month at a deeply discounted hourly rate. , ... has a progressively discounted rate. Subscription hours are contracted ...
(Date:12/22/2014)... News) -- U.S. and state health officials are investigating ... killed at least four people and sickened 28 others ... commercially produced, prepackaged caramel apples until more information becomes ... said in a news release. As of Dec. ... with the outbreak strains of the bacteria Listeria ...
Breaking Medicine News(10 mins):Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 3Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:CDC Warns of Listeria Danger From Caramel Apples 2
... Speaker Nancy Pelosi,delivered remarks this morning at the ... members of Congress, and hundreds of,children and seniors. ... full,funding of the State Children,s Health Insurance Program ... ask me what the three most important issues ...
... BETHESDA, Md., Sept. 6 Montana native and health ... Center Billings, MT, has been,installed to the post ... Health Centers (NACHC). Ceremonies took place at NACHC,s ... in Dallas, TX,which drew thousands of health center ...
... to make open-heart,surgery a minimally invasive procedure ... of Health Bioengineering Research Partnership award.,Professor Pierre ... surgeon Pedro del Nido, M.D., at Children,s ... Inc. (Van Nuys,CA) will collaborate to develop ...
... finds it brings the patient real benefit, too , ... partners with Alzheimer,s disease report better physical health if ... shows. , "Preserving the health of spouse caregivers through ... disease, as caregivers who are in poor health are ...
... 6 In response to,reports about the potential closure ... today reassured employees that the,civil section of the facility ... of closing the civil section of Warren,State Hospital and ... in,which residents and counties have come to depend," said ...
... on most common cause of inherited mental ... impairment and Parkinson-like syndrome, SAN FRANCISCO, ... California, Davis, School of Medicine and the M.I.N.D.,Institute, in collaboration ... Interdisciplinary Research Consortium grant from,the National Institutes of Heath, the ...
Cached Medicine News:Health News:Pelosi: SCHIP Bill a Giant Step for America's Children 2Health News:Montana Health Care Leader Elected Board Chair of National Association 2Health News:Minimally Invasive Heart Surgery Research Wins N.I.H. Award 2Health News:Counseling Boosts Alzheimer's Caregivers' Health 2Health News:PA Secretary of Public Welfare Responds to Warren State Hospital Closure Rumors 2Health News:$21.8 Million NIH Grant for Fragile X Research 2Health News:$21.8 Million NIH Grant for Fragile X Research 3Health News:$21.8 Million NIH Grant for Fragile X Research 4
... The VacoSplint has a rigid shell with ... an immobilized foot/ankle. The VacoSplint is a non-weight ... weight bear he/she should transfer to the STORM ... remove the nylon liner from the STORM and ...
The Active Ankle Trainer model provides medial/lateral support and optimum ankle mobility for chronic and prophylactic use....
... Walker Pediatric Boot is the ... boot that offers superior comfort ... two sizes are offered thus ... will fit left or right, ...
... features a more open design of our ... Conformer boots. It is used to treat ... patients, plantar fasciitis, bone bruises (stone bruises), ... foot condition that might respond well to ...
Medicine Products: